Alessio Cantore
Group Leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (15)
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
The efficacy of hemophilia B (HB) replacement therapy is evaluated by coagulation factor IX (FIX) activity in plasma, although FIX bound to extravascular type IV collagen (Col4) also contributes to efficient hemostasis. Here, we investigated the impact of engineering FIX for improved (K5R) or reduced (K5A) Col4 binding on the pharmacokinetic properties of FIX Padua, fused to human serum albumin (HSA QMP ) engineered for favorable neonatal Fc receptor (FcRn) engagement. Hyperactive features and extended plasma half-life in human FcRn expressing mice, attributed to FIX Padua and HSA QMP engineering, respectively, was confirmed. In HB mice, Padua KA -HSA QMP exhibited negligible extravascular distribution and the highest plasma levels at early time points followed by the steepest decay. Conversely, Padua KR -HSA QMP showed increased extravascular distribution and a 3-fold longer functional half-life (80 hours). These findings support the use of Padua KA -HSA QMP and Padua KR -HSA QMP as hyperactive short- or long-term therapeutics, respectively, with opportunities for tailored HB replacement therapy.
Year:
2025
Year:
2025
Year:
2025
The liver is an essential organ of the body that performs several vital functions, including the metabolism of biomolecules, foreign substances, and toxins, and the production of plasma proteins, such as coagulation factors. There are hundreds of genetic disorders affecting liver functions and, for many of them, the only curative option is orthotopic liver transplantation, which nevertheless entails many risks and long-term complications. Some peculiar features of the liver, such as its large blood flow supply and the tolerogenic immune environment, make it an attractive target for in vivo gene therapy approaches. In recent years, several genome-editing tools mainly based on the clustered regularly interspaced short palindromic repeats associated protein 9 (CRISPR-Cas9) system have been successfully exploited in the context of liver-directed preclinical or clinical therapeutic applications. These include gene knock-out, knock-in, activation, interference, or base and prime editing approaches. Despite many achievements, important challenges still need to be addressed to broaden clinical applications, such as the optimization of the delivery methods, the improvement of the editing efficiency, and the risk of on-target or off-target unwanted effects and chromosomal rearrangements. In this review, we highlight the latest progress in the development of in vivo liver-targeted genome editing approaches for the treatment of genetic disorders. We describe the technological advancements that are currently under investigation, the challenges to overcome for clinical applicability, and the future perspectives of this technology.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Collaborators (12)
Antonella Forlino
University of Pavia
Chiara Brombin
Assistant Professor in Statistics SECS-S/01 (RTD-B)
Università Vita Salute San Raffaele
Valentina Capo
Staff Scientist
San Raffaele Telethon Institute for Gene Therapy
Matteo Iannacone
Director
Vita-Salute San Raffaele University
Carmen Unzu
Principal Investigator
Center for Applied Medical Research
Davide Mazza
Deputy Director
Ospedale San Raffaele
Giuseppe Ronzitti
Researcher
INSERM
Giuseppe Valacchi
David Murdock Distinguished Professor
North Carolina State University
Samuel Zambrano
Vita-Salute San Raffaele University
Elena Barbon
San Raffaele Telethon Institute for Gene Therapy
Stefano Beretta
San Raffaele Telethon Institute for Gene Therapy
Alessio Branchini
Senior Assistant Professor of Molecular Biology
University of Ferrara
Make your next move.
Prepare your application
Review drafts before you send them.